2020 World Congress Program At-A-Glance

Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

User shared 1-year progress using finasteride 1mg and minoxidil, regaining hair density. Others praised the improvement and asked about side effects and additional treatments.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.